179 related articles for article (PubMed ID: 17389009)
1. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors.
Walker JB; Bajzar L
J Thromb Haemost; 2007 Jun; 5(6):1257-64. PubMed ID: 17389009
[TBL] [Abstract][Full Text] [Related]
2. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.
Walker JB; Bajzar L
J Biol Chem; 2004 Jul; 279(27):27896-904. PubMed ID: 15128744
[TBL] [Abstract][Full Text] [Related]
3. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis.
Schneider M; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13333-9. PubMed ID: 14715655
[TBL] [Abstract][Full Text] [Related]
4. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
Mutch NJ; Thomas L; Moore NR; Lisiak KM; Booth NA
J Thromb Haemost; 2007 Apr; 5(4):812-7. PubMed ID: 17388801
[TBL] [Abstract][Full Text] [Related]
5. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
[TBL] [Abstract][Full Text] [Related]
6. Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin.
Kovács A; Szabó L; Longstaff C; Tenekedjiev K; Machovich R; Kolev K
Thromb Res; 2014 Jan; 133(1):80-7. PubMed ID: 24094605
[TBL] [Abstract][Full Text] [Related]
7. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
8. Increased urokinase and consumption of α
Longstaff C; Locke M
J Thromb Haemost; 2019 Jan; 17(1):195-205. PubMed ID: 30451372
[TBL] [Abstract][Full Text] [Related]
9. Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
Coleman JR; Moore EE; Kelher MR; Jones K; Cohen MJ; Banerjee A; Silliman CC
J Trauma Acute Care Surg; 2023 Jun; 94(6):857-862. PubMed ID: 36787438
[TBL] [Abstract][Full Text] [Related]
10. The kinetics of plasmin inhibition by aprotinin in vivo.
Kang HM; Kalnoski MH; Frederick M; Chandler WL
Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
[TBL] [Abstract][Full Text] [Related]
11. Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis.
Morishima Y; Kamisato C; Honda Y
J Thromb Thrombolysis; 2020 Jan; 49(1):94-99. PubMed ID: 31396790
[TBL] [Abstract][Full Text] [Related]
12. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.
Weitz JI; Leslie B; Hirsh J; Klement P
J Clin Invest; 1993 Apr; 91(4):1343-50. PubMed ID: 7682569
[TBL] [Abstract][Full Text] [Related]
13. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
14. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
[TBL] [Abstract][Full Text] [Related]
15. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin.
Schneider M; Brufatto N; Neill E; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13340-5. PubMed ID: 14715654
[TBL] [Abstract][Full Text] [Related]
16. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
[TBL] [Abstract][Full Text] [Related]
17. Platelets and soluble fibrin promote plasminogen activation causing downregulation of platelet glycoprotein Ib/IX complexes: protection by aprotinin.
de Haan J; van Oeveren W
Thromb Res; 1998 Nov; 92(4):171-9. PubMed ID: 9840026
[TBL] [Abstract][Full Text] [Related]
18. Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss.
Mastroroberto P; Chello M; Zofrea S; Marchese AR
Eur J Cardiothorac Surg; 1995; 9(3):143-5. PubMed ID: 7540397
[TBL] [Abstract][Full Text] [Related]
19. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
Kojima T; Gando S; Morimoto Y; Mashio H; Goda Y; Kawahigashi H; Kemmotsu O
Thromb Res; 2001 Dec; 104(5):301-7. PubMed ID: 11738071
[TBL] [Abstract][Full Text] [Related]
20. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin.
Aoki N; Moroi M; Tachiya K
Thromb Haemost; 1978 Feb; 39(1):22-31. PubMed ID: 77050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
